BioSpace News Archive

Signifier Medical Technologies Ltd, a pioneer in patient-friendly therapies for sleep disordered breathing, announced that it has successfully raised $35 million in its Series D capital raise.

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”),; announced today that it has engaged Biologics Consulting, a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices, to help facilitate progression of investigational new drug (IND) candidates through the regulatory pipeline.

Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, is providing an update on its MDNA11 program today

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today preliminary data demonstrating administration of its universal donor adult stem cell product, JadiCell, reduced pulmonary pathology in an animal model replicating the severe inflammation observed in patients infected with the COVID-19 delta variant.

Aloe Care Health today announced that the United States Patent and Trademark Office (USPTO) issued Aloe Care Patent No: 11,064,339 for its Emergency Event Detection and Response System.

IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly address allergic disease, today announced that it has raised $25 million in an oversubscribed Series A1 financing.

ImmunityBio, Inc., a publicly traded immunotherapy company, announced today that it has been granted a patent by the U.S. Patent and Trademark Office for its proprietary NANT Cancer Vaccine (U.S. Patent 11,071,774).

BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory Board (SAB).

AXON NEUROSCIENCE SE announced it will present new results from its Phase II clinical study of its tau vaccine AADvac1 against Alzheimer’s disease at the 2021 Alzheimer’s Association International Conference, which is being held in Denver, Colorado and virtually, 26th - 30th July.